FDA Approves Sunharbo (Asundexian) 50 Mg Tablets
The FDA approved Bayer's Sunharbo (asundexian) 50 mg tablets to reduce stroke risk, described in the headline as the first Factor XIa inhibitor for this use.
Related stories
Trump Withdraws MacNeil’s Nomination For FTC Commissioner
L impact | REGULATION | Nov 09, 2026, 10:58 PM UTC
Bayer Wins US FDA Approval For Potential Blockbuster Stroke Drug
L impact | REGULATION | Nov 09, 2026, 10:42 PM UTC
FDA Approves Bayer’s Sunharbo For Stroke Prevention
L impact | REGULATION | Nov 09, 2026, 10:19 PM UTC
Dow-X-energy SMR Project Receives Construction Permit
The U.S. Nuclear Regulatory Commission issued a construction permit for the proposed small modular reactor project at Dow’s industrial site.
M impact | REGULATION | Nov 09, 2026, 09:17 PM UTC
CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA Decision
Shares of Capricor Therapeutics (CAPR) rose about 8% on Monday after the company said that cardiac results from its HOPE-3 late-stage trial of Deramiocel in Duchenne muscular dystr
L impact | REGULATION | Nov 09, 2026, 08:13 PM UTC
US Sec. of Defense Hegseth's impeachment articles are introduced in the House.
L impact | REGULATION | Nov 09, 2026, 07:07 PM UTC